Eximia Research Acquires Tidewater Clinical Research 

Eximia Research Acquires Tidewater Clinical Research 

On July 31, Eximia Research announced that it acquired Tidewater Clinical Research, a contract research organization (CRO) that is based in Norfolk, Virginia.  Since 1994, Tidewater Clinical Research has been at the forefront of women’s health research in the Hampton Roads/Eastern Virginia region. With a substantial patient database and a strong network of investigators, Tidewater has conducted numerous clinical trials that have significantly advanced medical knowledge and patient care.  Eximia is a multi-site, multi-therapeutic, clinical research site network serving pharmaceutical, biotech companies and CROs and providing Phase I-IV research services across a diverse... Read More »
Tobin Scientific Acquires BioRepository Resources 

Tobin Scientific Acquires BioRepository Resources 

On July 2, Tobin Scientific announced that it acquired all assets of BioRepository Resources, LLC.   BioRepository Resources, LLC is a specialty contract services company that is focused on regulated long-term storage of biological and pharmaceutical materials. It is based in New Providence, New Jersey.   Tobin Scientific is a leading provider of biopharma cold chain, ambient storage and transport and logistics services. It is based in Beverly, Massachusetts and was founded in 1960. It has more than 300,000 square feet of ambient warehouse space and a robust portfolio of specialized transport and storage services.  This strategic acquisition enhances Tobin Scientific’s... Read More »
HiRO Acquires DeltaMed Solutions, Continues to Expand U.S. Footprint

HiRO Acquires DeltaMed Solutions, Continues to Expand U.S. Footprint

Harvest Integrated Research Organization (HiRO), has announced the successful acquisition of DeltaMed Solutions, headquartered in Somerset, New Jersey. The acquisition, advised by Evercore as financial advisor, marks HiRO’s third CRO acquisition since its establishment in 2020. DeltaMed Solutions is a global life sciences contract research organization (CRO) with a global footprint in the United States and China. DeltaMed Solutions, headquartered in New Jersey, boasts a team of industry professionals with 15-30 years of expertise in serving large to mid-sized pharmaceutical and biotechs. HiRO is a globally oriented CRO with its headquarters in Shanghai, China. With global operations... Read More »
Tobin Scientific Acquires BioRepository Resources 

TPG Invests in K2 Medical Research 

On June 17 TPG announced that it was making a significant growth investment in K2 Medical Research.   K2 Medical Research is a leading clinical research organization (CRO) dedicated to advancing medical science through the efficient and ethical conduct of clinical trials. Its integrated clinical trial site platform specializes in central nervous system trials for leading pharma and biotech sponsor and is focused around complex therapeutic areas including Alzheimer’s, psychiatry and liver disease. The company is based in Florida and operates seven locations across the state.  TPG is a global alternative asset management firm with $137 billion of assets under management and... Read More »
HiRO Acquires DeltaMed Solutions, Continues to Expand U.S. Footprint

Formosa Laboratories Expands North American CRO/CDMO Footprint

Formosa Laboratories, Inc. announced that it has successfully completed its acquisition of SynChem, Inc., headquartered in the Chicago MSA suburb of Elk Grove Village. Founded in 1997, SynChem is a chemistry-based contract research organization (CRO) specializing in organic synthesis, process development and medicinal chemistry. Since its inception, SynChem has completed more than 4,500 projects for wide range of customers, including multi-national pharmaceutical companies, biotech companies, drug discovery companies and chemical and agrochemical companies. Founded in 1995, Formosa Laboratoriesap is a leading active pharmaceutical ingredients (API) supplier and contract development and... Read More »
Fortrea Divests Assets to Arsenal Capital Partners for $345 Million 

Fortrea Divests Assets to Arsenal Capital Partners for $345 Million 

Fortrea, a Durham, North Carolina-based global contract research organization (CRO), is divesting certain assets to Arsenal Capital Partners for $345 million.   The assets being divested relate to Fortrea’s Enabling Services segment, including the businesses Endpoint Clinical and Fortrea Patient Access. In 2023, Fortrea generated revenues of about $3.11 billion compared to about $3.1 billion the previous year, according to the original press release.  Arsenal is a New York, New York-based private equity firm that specializes in investments in healthcare and industrial growth companies. Since its inception in 2000, Arsenal has raised institutional equity investment funds of more... Read More »